| Hematologic
diseases |
aPTT* b(24’’-36’’) |
free PS ** b(F 58-113%)
(M 72-123%) |
PC** b (70-140%) |
AT III** b (70-120%) |
D-Dimer
( <0.5 μg/ml) |
| HSa |
28.6 ± 3.1 |
87.2 ± 15.3 |
89.4 ± 8.8 |
93.1 ± 7.8 |
<0.5 |
| PK deficita |
36.8 ± 4.7 |
55.6 ± 13.1 |
64.8 ± 12.1 |
62.5 ± 5 |
>0.5 |
| CD IIa |
37.3 ± 5.2 |
47.4 ± 6 |
58.7 ± 5.4 |
59.2 ± 7.8 |
>0.5 |
| cITPa |
29.7 ± 3.3 |
91.4 ± 14.3 |
94.1 ± 7 |
93.1 ± 7.2 |
<0.5 |
| TIa |
36.2 ± 2.8 |
50.7 ± 5.2 |
58.4 ± 7 |
60. 2 ± 5 |
>0.5 |
| HCa |
27.9 ± 2.9 |
96 ± 11 |
98 ± 28 |
103 ± 9 |
<0.5 |
a PTT* p< 0.05 PK deficit, CDII, TI vs HS, Citp, HC
PS,PC, ATIII** p< 0.05 PK deficit, CDII, TI vs HS, cITP, HC
ªHereditary Spherocytosis: HS; Piruvate Kynase Deficit: PK; Congenital
Dyserithropoiesis II: CDII; Chronic Idiopathic
Thrombocytopenic Purpura: cITP; β thalassemia intermedia: TI
b Activated Partial Thromboplastin Time: (aPTT), Free Protein C activity:
(PC); Protein S: (PS), Antithrombin III: (AT III); D: Dimer |
